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Abstract
Background:  Chronic obstructive pulmonary disease (COPD) is a significant health problem worldwide. This
randomised controlled trial aims at testing a new approach that involves a registered nurse working in partnership with
patients, general practitioners (GPs) and other health professionals to provide care to patients according to the evidence-
based clinical practice guidelines. The aim is to determine the impact of this partnership on the quality of care and patient
outcomes.
Methods: A cluster randomised control trial design was chosen for this study. Randomisation occurred at practice level.
GPs practising in South Western Sydney, Australia and their COPD patients were recruited for the study.
The intervention was implemented by nurses specifically recruited and trained for this study. Nurses, working in
partnership with GPs, developed care plans for patients based on the Australian COPDX guidelines. The aim was to
optimise patient management, improve function, prevent deterioration and enhance patient knowledge and skills.
Control group patients received 'usual' care from their GPs.
Data collection includes patient demographic profiles and their co-morbidities. Spirometry is being performed to assess
patients' COPD status and CO analyser to validate their smoking status. Patients' quality of life and overall health status
are being measured by St George's Respiratory Questionnaire and SF-12 respectively. Other patient measures being
recorded include health service use, immunisation status, and knowledge of COPD. Qualitative methods will be used to
explore participants' satisfaction with the intervention and their opinion about the value of the partnership.
Analysis: Analysis will be by intention to treat. Intra-cluster (practice) correlation coefficients will be determined and
published for all primary outcome variables to assist future research. The effect of the intervention on outcomes
measured on a continuous scale will be estimated and tested using mixed model analysis of variance in which time and
treatment group will be fixed effects and GP practice and subject nested within practice will be random effects. The effect
of the intervention on the dichotomous variables (such as smoking status, patient knowledge) will be analysed using
generalised estimating equations with a logistic link and a model structure that is analogous to that described above.
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Background
Significance of COPD
Chronic obstructive pulmonary disease (COPD) is a lead-
ing cause of disability, hospital admission and premature
mortality in men and women [1]. According to WHO esti-
mates, there are 210 million people worldwide who have
COPD [2]. In 2005, there were 3 million deaths from
COPD globally and the projection is that the mortality
from COPD will increase by 30% over the next 10 years
unless urgent actions are taken to combat it [2].
The prevalence of COPD (GOLD stage 2 or higher, that is
post-bronchodilator FEV1/FVC ratio < 0.7 and FEV1 < 80%
predicted) in a representative sample of people aged 40
years and over living in south-east Sydney in 2006 was
10.8%. This was in the mid-range of estimates for centres
in 12 countries that participated in the first round of the
BOLD international comparative study [3]. In recent years
there has been a decline in death rates from COPD, but it
still remains the fifth leading cause of death for males
(40.6 deaths/100,000 population) and the seventh lead-
ing cause of death for women (19.5 deaths/100,00 popu-
lation) in Australia [4].
In addition to the significant social and economic burden
of deaths caused by COPD, the condition also poses a sig-
nificant burden on the Australian health care system
through hospitalisation of COPD patients with complica-
tions. In 2001–02, COPD led to 51,621 admissions Aus-
tralia-wide, with an average stay of 7.5 days [3].
Nationwide, costs of COPD including hospitalisation,
together with related community medical care, pharma-
ceutical services and indirect costs such as lost productiv-
ity are estimated to be in the range of 820 – 900 million
Australian dollars annually [5].
Evidence-based management
Guidelines for diagnosis and management of COPD are
now available. In Australia the COPDX guidelines are
commonly used which detail recommendations for pre-
venting or slowing disease progression and optimising
function for COPD patients [6]. The key recommenda-
tions include:
￿ Smoking cessation
￿ Pulmonary rehabilitation
￿ Influenza vaccination
￿ Optimising the use of inhaled bronchodilators & corti-
costeroids
￿ Patient education.
Despite the publication of the COPDX guidelines there is
a low level of awareness about the existence of such guide-
lines among GPs in Australia [7]. To reduce the impact of
COPD in Australia initiatives to encourage GP uptake of
guideline recommendation are warranted.
Role of General Practice in COPD management
General practice is well placed to provide early interven-
tion and management of COPD patients. In Australia,
general practice is the most common point of contact in
the health system as 87% of people visit their GPs at least
once a year [8]. COPD accounts for 0.6% of all problems
managed in general practice [9]. While improved care in
the community has the potential to substantially improve
outcomes, research to date suggests that GPs experience
difficulties providing care for patients with chronic illness
under the current model of care which is largely encounter
based and does not involve non-GP health providers [10].
There is a need for more structured systems to implement
chronic illness care such as a multidisciplinary care plan.
The use of care plans has become a recommendation for
the management of people with chronic illnesses such as
diabetes and asthma [11-13]. Similar to these patients,
COPD patients often have complex needs and the
COPDX guidelines[6] recommend the use of multidisci-
plinary care plans. However, research suggests that GPs
need more external support to develop and implement
multidisciplinary care plans for these patients [14-16].
Role of nurses in care of COPD
A review of the roles of specialised nurses in care of
patients with diabetes or COPD found evidence that they
improved patient self care, quality of life and satisfaction
[17]. A Cochrane review revealed that a nurse outreach
program involving nurse home visits to COPD patients
providing support and education, monitoring health sta-
tus and providing liaison with physicians resulted in
improved quality of life and reduced mortality [18]. A
New Zealand study, that involved practice nurses and GPs
implementing a care plan with advice from a respiratory
nurse and specialist physician, resulted in reduced hospi-
tal admissions and reduced hospital bed days and there
were significant improvements in spirometry [19].
Lesson learnt from a previous study
A randomised controlled trial (RCT) [20] conducted in
1998–99 which evaluated the effect of a brief, nurse-led
intervention at 1 week and 4 weeks interval after discharge
from hospital on clinical outcomes in patients with
COPD. The aim was to evaluate the efficacy of limited
community based care provided by nurses to COPD
patients. Results from this study demonstrated limited
success. There were some improvements in activity and
knowledge scores of patients in the intervention group
and they were more satisfied with their care, but there wasBMC Pulmonary Medicine 2008, 8:8 http://www.biomedcentral.com/1471-2466/8/8
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no impact on rates of emergency department presentation
and hospital readmission. We subsequently attributed the
failure of the intervention to three key reasons 1) GPs
were not sufficiently involved in the patient care (evident
by the fact that only 31% of the GPs recalled having
received patient related information (care plan) from the
nurses), 2) there was no formal partnership between GPs
and nurses streamlining patient care, and 3) the unavaila-
bility of universally accepted guidelines for management
of COPD such as, COPDX.
Aim of the study
The aim of this study is to test a new approach to improv-
ing the care of patients with COPD managed in general
practice. The intervention involves a registered nurse with
specific training working in partnership with the patient,
GPs and other health professionals to provide evidence-
based care according to the Australian COPDX guidelines.
The research aims to determine the impact of this partner-
ship on the quality of care and health outcomes for
patients with COPD at six and 12 months follow-up.
These are the hypotheses being tested:
1. That in patients with COPD, the intervention improves
disease-related quality of life and overall health including
patient health status, lung function and health service use.
2. That the intervention improves the quality of care pro-
vided to patients with COPD and that this will impact on
knowledge, immunisation compliance, smoking cessa-
tion and satisfaction with care.
Research Plan
A cluster randomised control trial design has been chosen
for this study. As GPs find it difficult to selectively offer
interventions to their patients, the cluster design was
implemented to avoid contamination between interven-
tion and control groups. Randomisation occurred at prac-
tice level and an adjustment to the sample size estimates
allowed for clustering.
Recruitment
General Practitioner/practice recruitment
GPs were recruited from a list of 256 GPs practising in
South Western Sydney (SWS). The list includes GPs who
have previously participated in research and/or attended
local continuing medical education (CME) activities and
also includes the chief investigators' personal contacts.
Letters of invitation were sent to these GPs with a copy of
the GP information statement. Within one to two weeks
of the initial invitation telephone contacts were made
with the GPs by one of the chief investigators to explain
the study, check their eligibility, answer their questions
about the study and formally invite them to participate.
The GPs expressing interest were visited by the chief inves-
tigator at their practices. At the practice visit the details of
involvement were explained and written consent was
obtained. Inclusion criteria for GPs were: practising in
SWS, use of an electronic prescribing system, and having
seen COPD patients in the past 12 months. The aim was
to recruit at least 40 GPs.
Patient recruitment
Participating GPs were asked to search their electronic pre-
scription records and identify patients who had been pre-
scribed medications for COPD. These were defined as
inhaled beta 2-agonists, inhaled corticosteroids, ipratro-
pium bromide, tiotropium, oral theophylline and oral
corticosteroids. Patients' were eligible if they were aged
between 40 and 80 years, prescribed one or more of the
above medications, have seen the GP in the previous 12
months, and had a clinical diagnosis of either COPD,
emphysema or chronic bronchitis. Patients who lived out-
side SWS, did not speak English, or had significant cogni-
tive impairment were excluded from the study.
Letters were sent to the eligible patients inviting them to
take part in the study. The letters included a patient infor-
mation sheet and a consent form. Those who consented to
take part returned the form to the research team. The
project officer from the research team then contacted
these patients and organised a home visit (or at the GP
surgery if preferred by patient) to collect the baseline data
as detailed below.
Two two-weekly reminders were sent to the non-respond-
ing patients. The aim was to recruit 400 patients from 40
GPs (an average 10 patients per GP).
Randomisation
Practices were allocated to intervention and control
groups according to a computer generated list comprising
11 randomly permuted blocks of size four. A system of
sealed envelopes was used; a sealed envelope for each
block contained four sequentially labelled sealed enve-
lopes. A researcher not involved with the study and blind
to the identity of the GPs undertook the randomisation.
Once baseline data collection had been completed for the
patients visiting a number of practices the practices were
stratified according to whether they had recruited more
than ten patients or less than ten patients and then allo-
cated to a block of four. The envelope was opened and the
individual practices were allocated to intervention or con-
trol depending on the contents of the four sequentially
labelled envelopes. The research nurses and GPs were
informed of the intervention allocation by the study
administrator. The data collection staff remained blind to
the allocation to prevent bias in data collection.BMC Pulmonary Medicine 2008, 8:8 http://www.biomedcentral.com/1471-2466/8/8
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Intervention
The intervention was implemented by nurses specifically
recruited for this study. Nurses worked in partnership
with GPs to implement the intervention. Nurses had been
specifically trained to enable them to successfully imple-
ment the intervention. The training program for the
nurses included attendance at a two-day workshop where
the following topics were presented by expert clinicians:
patho-physiology of COPD, assessment of COPD,
spirometry, smoking cessation, management of COPD
according to COPDX guidelines, role of pulmonary reha-
bilitation in the management of COPD, and the manage-
ment of exacerbations.
Intervention process
The intervention nurses worked with GPs, patients and
other care providers as shown in Figure 1. Patients in the
intervention group received two home visits and five tele-
Figure 1BMC Pulmonary Medicine 2008, 8:8 http://www.biomedcentral.com/1471-2466/8/8
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phone contacts from the nurse and a minimum of two
consultations with their GP over a six-month period. The
nurse and GP met face to face on two occasions and fur-
ther consultation between the nurse and GP took place by
telephone monthly or more frequently as needed to dis-
cuss progress and problems of the patients involved.
Care plan content
The care plan is based on the recommendations of the
COPDX evidence-based guidelines [6]. The plan aimed to
optimise management, improve function, prevent deteri-
oration and enhance patient knowledge and skills. The
care plan was individualised to meet the needs of the
patients and contained relevant components of the fol-
lowing:
1. Smoking cessation
2. Immunisation status
3. Pulmonary rehabilitation
4. Medication review
5. Nutrition
6. Psychosocial issues
7. Patient education
8. Co-morbidities and complications of COPD
Control Group
Patients in the control group received 'usual' care from
their GPs. They were provided with a copy of the COPDX
guidelines. 'Usual' care is defined as processes normally
followed by the GP and the patient regarding review,
pharmacological therapy and management of COPD.
Outcome evaluation
Quantitative outcomes were measured using instruments
with demonstrated validity and reliability. A portable car-
bon monoxide (CO) analyser was used to validate partic-
ipants' self-report of smoking status. These measures were
implemented by two members of the research team who
were blinded to the patients' group allocation. Data col-
lectors received training in spirometry and use of the CO
analyser.
Outcomes were measured at three points in time – at
recruitment (baseline), 6 months and at 12 months after
randomisation. [Table 1 shows outcomes measures being
collected] These were measured at the participant's resi-
dence or at the GP practices as preferred by the patient.
Qualitative data about the value of the nurse-GP partner-
ship and the role of the care plan will be collected from
the intervention group by structured interviews at the con-
clusion of the project following collection of the 12
month quantitative outcomes.
Baseline measures
Patient demographic details such as age, gender, employ-
ment status, education, and country of birth are recorded
at baseline. Information regarding their COPD and smok-
ing history are also collected at baseline. Spirometry is
performed to assess their COPD status and CO analyser is
used to validate their smoking status. Co-morbidity is
assessed using two measures: the Geriatric Index of
Comorbidity [21] and the number of classes of medica-
tion used.
Table 1: Schedule of data collection
At identification At recruitment 6-months 12-months
Age, gender, language spoken X X
Demographic information X
Index of Comorbidity X
Number medication classes X X* X
St George's Resp Ques X X X
Spirometry XX X
Immunisation status X X X
Patient knowledge of COPD X X X
Patient satisfaction with care X X X
Smoking status: self-report X X X
CO analyser X X X
Health status (SF12) X X X
Health service use X X X
Value of partnership X X X
Role and value of care plan X
* respiratory medications onlyBMC Pulmonary Medicine 2008, 8:8 http://www.biomedcentral.com/1471-2466/8/8
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Quantitative outcome measures
Patient quality of life: (hypothesis 1) was assessed using
the St George's Respiratory Questionnaire (SGRQ) [22] at
baseline and 12 month follow up. The SGRQ is a self-
administered instrument designed specifically for respira-
tory disease. It is a 50-item instrument from which are cal-
culated a total score and three component scores:
symptoms (distress caused by respiratory symptoms),
activity (physical activities thai are limited by breathless-
ness) and impacts (social and psychological effects of the
disease). The SGRQ is scored from zero to 100 where zero
indicates best quality of life and 100 worst. A change in
score of four is considered to be clinically significant
[22,23].
Lung function: (hypothesis 1) Spirometric function was
measured before and 10 minutes after the administration
of 200 μg sulbutamol via large volume spacer, according
to standard methods. Forced expiratory volume in one
second (FEV1) and forced vital capacity (FVC) were
recorded.
Patient health status: (hypothesis 1) was measured using
the SF-12 [24], a generic measure of health impairment.
The SF-12 gives two scores, the mental components scale
and the physical component scale, which both have a
mean of 50 and a standard deviation of 10.
Health service use: (hypothesis 1) the number and type of
general practice, specialist, community health, and hospi-
tal services used during the 12 months study period were
recorded using a patient checklist of services.
Immunisation status: (hypothesis 2) details of immunisa-
tion status for influenza and pneumococcal infection were
collected by patient report.
Patient knowledge (hypothesis 2) of the steps that can be
taken to reduce the progression of COPD was assessed
using the same measure as in the previous trial [20].
Patients were asked to name up to three things that they
could do to prevent progression of their lung disease.
Patient satisfaction: (hypothesis 2) with the overall man-
agement will be measured at 12 months using the ques-
tionnaire used in our previous study [20]. In addition,
focus groups will also be conducted with a sub-set of
patients in the intervention group to explore the issues
even further.
Smoking status and cessation: (hypothesis 2) the smoking
status of patients at baseline was established by recording
the number of cigarettes smoked and the length of time
before the first cigarette in the morning (a measure of
addiction) [25]. Attendance at a smoking cessation pro-
gram and quit rates were recorded.
Qualitative process measures
Value of the nurse and GP partnership
Structured interviews with the respiratory nurses and the
GPs will examine satisfaction with the program and per-
ceptions of the value of working together. Structured
interviews with patients will explore the effects and value
of the nurse input into COPD care. The software package
NVivo® will be used to facilitate coding, and exploration of
the data.
Statistical Analysis
Data are stored in an Access database and will be exported
for analysis to SPSS. Analysis will be by intention to treat.
Intra-cluster (practice) correlation coefficients will be
determined and published for all primary outcome varia-
bles to assist future research. Potential confounders will
be compared between groups to confirm that the ran-
domisation has provided the appropriate balance.
The effect of the intervention on outcomes measured on a
continuous scale (such as SGRQ score) will be estimated
and tested using mixed model analysis of variance in
which time and treatment group will be fixed effects and
GP practice and subject nested within practice will be ran-
dom effects. The effect of the intervention on the dichoto-
mous variables (such as smoking status, patient
knowledge) will be analysed using generalised estimating
equations with a logistic link and a model structure that is
analogous to that described above.
Sample size calculations
The primary outcome variable will be 'between group' dif-
ferences in post-test (12-months) is mean SGRQ scores.
Data from our previous study [20] demonstrates that the
between subject standard deviation in SGRQ scores is 13.
The recommended minimum detectable difference to use
for sample size calculations with SGRQ is 4.0 [22,23]. We
have based our calculations on a intra-cluster correlation
coefficient of 0.01 and a resultant design effect of 1.09 for
a cluster size of 10 [26]. With this design effect the study
has a > 80% power to detect a difference of 4 or greater in
SGRQ. This requires at least 20 practices in each group
and at least 10 patients per practice and that is at least 200
subjects in each group, (calculations in PASS software).
We estimated that the prevalence of COPD among general
practice patients would be about 4.0%, slightly higher
than population estimates [3]. Assuming that there are
1,500 adult patients registered with each GP then we
would expect that there would be 60 patients with COPD.
If a third of these patients would be eligible and consent
to participate in the study, thus we will recruit 20 patientsBMC Pulmonary Medicine 2008, 8:8 http://www.biomedcentral.com/1471-2466/8/8
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per practice. Taking a conservative approach and assum-
ing 10 patients consent per practice, then to achieve 400
patients we will need to recruit 40 GP practices. As previ-
ously stated there are currently 785 GPs in 467 practices in
SWS. Based on our previous experience of EPC evaluation
[14] where 71% of the GPs contacted took part in the
research we expect to be able to recruit the numbers of
GPs and practices needed for this efficacy trial.
Time plan for the study
The project was commenced in mid 2006. GP and patient
recruitment were completed in February 2008. The inter-
vention will be completed by April-May 2008 and then 6
month follow-up will commence. This will be followed
by 12 month follow-up later in the year and the project
will be completed by mid to late 2009.
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